Early Results of the Phase I/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
Year: 2023
Type: conference-abstract
Source: Blood
Authors: Ghayas C. Issa, Branko Cuglievan, Courtney D. DiNardo, Nicholas J. Short, David McCall, Amber Gibson, Cesar Nunez, Miriam B. Garcia, Michael Roth, Aram Bidikian, Allison Pike, Sheila Tan, Brianna Kammerer, Musa Yilmaz, Tapan M. Kadia, Naveen Pemmaraju, Maro Ohanian, Naval Daver, Elias Jabbour, Gautam Borthakur, Farhad Ravandi, Guillermo Garcia-Manero, Michael Andreeff, Hagop M. Kantarjian
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4389233215